Vedolizumab
- PDF / 169,751 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 86 Downloads / 140 Views
1 S
Vedolizumab Various toxicities: 14 case reports
In a multicentre retrospective cohort study of 303 patients with ulcerative colitis treated with vedolizumab, 14 patients [ages and sexes not stated] were described, who developed haemophagocytic syndrome due to cytomegalovirus (1 patient), Klebsiella sepsis (1 patient), nasopharyngitis (1 patient), pharyngitis (1 patient), pneumonia (1 patient), Strongyloides (1 patient), Campylobacter infection (1 patient), Salmonella infection (1 patient), buttock abscess (1 patient), oral thrush (1 patient), rash (1 patient), delayed hypersensitivity reaction (1 patient) arthralgia and headaches (1 patient) and gastroenteritis (1 patient) during treatment with vedolizumab for ulcerative colitis [duration of treatment to reaction onsets and outcomes not stated]. The patients, who had ulcerative colitis, received vedolizumab as standard IV induction dosing of 300mg at 0, 2 and 6 week followed by maintenance therapy of 8 weekly IV infusions. Subsequently, 2 patients developed a serious infection, of the 2 patients, 1 patient developed haemophagocytic syndrome due to cytomegalovirus and another patient developed Klebsiella sepsis; these 2 patients were on dual immunosuppression through out the study period. Also, nasopharyngitis (1 patient), pharyngitis (1 patient), pneumonia (1 patient), Strongyloides (1 patient), Campylobacter infection (1 patient), Salmonella infection (1 patient), buttock abscess (1 patient), oral thrush (1 patient), rash (1 patient), delayed hypersensitivity reaction (1 patient), arthralgia and headaches (1 patient) and gastroenteritis (1 patient) associated with vedolizumab were reported. Reddy Pulusu SS, et al. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World Journal of Gastroenterology 26: 4428-4441, No. 30, 14 Aug 2020. Available from: URL: http://doi.org/10.3748/WJG.V26.I30.4428
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803518278
Reactions 5 Dec 2020 No. 1833
Data Loading...
